Thursday 28 February 2019

Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD

Researchmoz added Most up-to-date research on "Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD" to its huge collection of research reports.

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. Conditions within the therapy area are diverse, and exhibit specific pathophysiologies and etiologies, while affecting people of all ages. 

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimers disease (AD), Parkinsons disease (PD) and multiple sclerosis (MS). AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates. 

As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1389106


Scope
Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
- What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS? 
- What is the current treatment algorithm? 
- How effective are current therapies for these indications, and how does this impact prognosis? 
The AD pipeline is large and contains a very high proportion of first-in-class product innovation.
- Which molecule types and molecular targets are most prominent across AD, PD and MS? 
- What are the connections, in terms of first-in-class innovation, between AD, PD and MS?
- Which first-in-class targets are most promising? 
- How does the level of first-in-class innovation change within different target classes?
- How do identified first-in-class molecular targets apply to AD, PD, MS and the wider therapeutic area? 
- How does first-in-class target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by immunomodulator products
- Which indications attract the highest deal values? 
- How has deal activity fluctuated over the past decade? 
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?


Browse TOC @ https://www.researchmoz.us/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd-report.html/toc


Reasons to buy
- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

Cancer Supportive Care Drug Development Booming with the Major Players Like Abreos Biosciences Inc, Novartis AG, BiologicsMD Inc, R Pharm and IntelGenx Corp

Researchmoz added Most up-to-date research on "Cancer Supportive Care Drug Development Booming with the Major Players Like Abreos Biosciences Inc, Novartis AG, BiologicsMD Inc, R Pharm and IntelGenx Corp" to its huge collection of research reports.

This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia-cachexia and asthenia, which is associated with weakness, fatigue, and a poor quality of life. Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394149

The size of these pipelines ranges 24 products in cancer anorexia-cachexia syndrome to 52 in cancer pain. The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development. Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand superfamily member 11, and the hepatocyte growth factor receptor, along with a range of others. Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range of ion channels, are the most common type of target, reflecting the pain treatment landscape in general.

Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/cancer-supportive-care-drug-development-pipeline-review-2017-report.html/toc

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Future Demand, Industry Analysis & Outlook Of Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

Researchmoz added Most up-to-date research on "Future Demand, Industry Analysis & Outlook Of Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017" to its huge collection of research reports.

This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394150

Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/gastric-and-esophageal-cancer-drug-development-pipeline-review-2017-report.html/toc

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Sickle Cell Disease Drug Development Pipeline Review Thriving Worldwide with Acceleron Pharma Inc, Bioverativ Inc, Daiichi Sankyo Co Ltd, Genethon SA and Novartis AG

Researchmoz added Most up-to-date research on "Sickle Cell Disease Drug Development Pipeline Review Thriving Worldwide with Acceleron Pharma Inc, Bioverativ Inc, Daiichi Sankyo Co Ltd, Genethon SA and Novartis AG" to its huge collection of research reports.

This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. There are a total of 62 products in development for this indication, by 45 companies and nine academic institutions. Hemoglobin and a range of histone deacetylases are the most common molecular targets being studied in sickle cell anemia.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. There are a total of 10 products in development for this indication.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394151

Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/sickle-cell-disease-drug-development-pipeline-review-2017-report.html/toc

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Most Definitive & Accurate Study Of Swine and Avian Influenza Drug Development Pipeline Review, 2017

Researchmoz added Most up-to-date research on "Most Definitive & Accurate Study Of Swine and Avian Influenza Drug Development Pipeline Review, 2017" to its huge collection of research reports.

This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. There are a total of 63 products in development for this indication, by 47 companies and six academic institutions.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by the contagious H1N1 influenza virus. There are a total of 99 products in development for this indication, by 67 companies and 14 academic institutions.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394152


In both types of influenza, the most common molecular target being studied is hemagglutinin, by a considerable margin. However, a number of both human and viral proteins are also under active development.

Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?


Browse TOC @ https://www.researchmoz.us/swine-and-avian-influenza-drug-development-pipeline-review-2017-report.html/toc


Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

COPD Therapeutics in Asia-Pacific Market Size, Growth Opportunities, Trends by Manufacturers | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis

Researchmoz added Most up-to-date research on "COPD Therapeutics in Asia-Pacific Market Size, Growth Opportunities, Trends by Manufacturers | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis" to its huge collection of research reports.

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. It occurs most often in older people, but can also affect the middle aged population. COPD is a major cause of chronic morbidity and mortality globally. Many people suffer from the disease for years and eventually die from it or its complications, meaning it constitutes a substantial economic and social burden. 

Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to disease risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition. The share of mortality attributed to COPD is expected to increase in the coming decades, when compared with other chronic diseases such as heart disease and stroke. The marketed products landscape comprises a wide range of treatment options, including bronchodilator combinations, bronchodilator and inhaled corticosteroid (ICS) combinations, bronchodilator monotherapies and PDE-4 inhibitors. 

However, the market is undergoing a gradual transition, moving away from bronchodilator and ICS therapies and towards targeted and triple-combination drug treatments. The market is set to be driven by recently launched products, and the approval of novel drugs that will supplement current market leaders and offer broader therapeutic options.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1434918

Scope
  • The COPD Asia-Pacific market will be valued at $6.7 billion in 2023, growing from $3.8 billion in 2016 at a CAGR of 8.7%.
  • Bronchodilators and ICS therapies dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
  • Do branded therapies show continuous growth, and are they facing competition from generics?
  • How will branded therapies be affected by upcoming pipeline therapies?
  • The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
  • What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
  • Various drivers and barriers will influence the market over the forecast period.
  • What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?


Reasons to buy
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.

Global Cardiovascular Disease Drugs Market to 2023 - Brief Analysis On Top Key players: Johnson & Johnson, AstraZeneca, Daiichi Sankyo, Sanofi and Pfizer

Researchmoz added Most up-to-date research on "Global Cardiovascular Disease Drugs Market to 2023 - Brief Analysis On Top Key players: Johnson & Johnson, AstraZeneca, Daiichi Sankyo, Sanofi and Pfizer" to its huge collection of research reports.

The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within blood vessels. As atheroma develops it causes the affected blood vessels to narrow, restricting blood flow to the body, brain or heart, depending on its locale.

It is also possible for the fibrous cap of this plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally, which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling risk factors. As such, the treatments usually fall within three categories: Anti-hypertensives, which aim to maintain blood pressure within a normal range; anti-dyslipidemic drugs, which aim to modify lipid levels to a normal range; and anti-thrombotic drugs, which aim to prevent thrombi formation by inhibiting the coagulation cascade or platelet aggregation.

There has been vast scientific innovation in the CVD therapeutics market in recent decades, particularly within the anti-dyslipidemia market. This was seen first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. However, other areas such as the heart failure market remain poorly treated. Dyslipidemia and hypertension have continuing high levels of development within the current pipeline and, despite high levels of generic development, there is also a large degree of innovation, with targets such as apolipoproteins and elements of the reverse lipid transport pathway. In addition, the current pipeline includes nearly 200 products for the treatment of heart failure, suggesting an increase in interest in treating the disease.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1473331


Scope
- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?
- The clinical trials process for CVD drugs is complex. What is the risk of a CVD drug failing to reach the market? What is the risk of a drug failing at a specific Phase?
- The CVD market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions. Which of the leading companies will have the highest market share by 2023? What strategies have these companies adopted to achieve market growth?
- There has been a moderately high level of deal activity in recent years. How do deal frequency and value compare between target families and molecule types?


Browse TOC @ https://www.researchmoz.us/global-cardiovascular-disease-drugs-market-to-2023-expiries-acquisitions-and-new-products-for-deep-vein-thrombosis-pulmonary-arterial-hypertension-and-dyslipidemia-to-shake-up-the-competitive-landscape-report.html/toc


Reasons to buy
- Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment.
- Recognize the leading therapeutics, as well as gaps in the market, with portfolios of key marketed products, including historical and forecast sales revenue patterns.
- Identify trends and developments, in terms of molecule type and molecular target, within the overall CVD pipeline, as well as for key CVD indications: hypertension, heart failure, dyslipidemia and thrombotic events.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
- Predict how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products and companies will make to this growth.
- Understand how strategic consolidations have shaped the current pipeline and marketed products landscape.

Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

Researchmoz added Most up-to-date research on "Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation" to its huge collection of research reports.

Transplantation Therapeutics

In 2015 a total of 127,000 transplantations were performed worldwide, an increase of 5.8% from 2014, with 33,000 of these occurring in the EU and 32,000 in the US. Approximately 60% of these were kidney transplants, with liver, heart, lung, pancreas and small bowel transplantations accounting for the other most common procedures (Dominguez-Gil and Matesanz, 2017). When a graft is transplanted from a genetically non-identical individual, the recipients immune system recognizes the graft as foreign.

This leads to an anti-graft immune response that involves T cells invading the new tissue, multiplying, and recruiting more immune cells to the transplant site in order to remove this foreign body. Depending on the nature of the incompatibility and the immune response, and acute or chronic rejection process can occur. Conversely, if the graft consists of hematopoietic stem cells or immune cells, there is a risk that they will mount an immune response against the host, known as graft versus host disease (GVHD). There are several safe pharmacological treatment options for acute rejections, but long-term treatment options remain unsatisfactory.


To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1473332


The risk of infection limits the effectiveness of these therapies, and improvements to their efficacy are also needed. Specific transplantation tolerance, in which alloreactive T cells are inactivated while the broader immune response is left intact, removing the need for broad immunosuppressant therapies, can be considered to be the ultimate goal for clinical transplantation. Compared with the overall immunology pipeline, in which there are 1,915 products, the transplantation pipeline is small, with only 244 products. However, of the 145 products in the transplantation pipeline with a disclosed molecular target, there are 65 first-in-class products, acting on a total of 63 distinct first-in-class targets, highlighting the fact that this pipeline displays strong levels of innovation.

Scope
- There is a need for therapies that can achieve graft-specific immunosuppression, without having a general effect on the wider immune system. Which therapies and technologies currently in development are most likely to achieve this?
- There are 63 distinct first-in-class molecular targets in development for transplantation. Which of these hold the strongest potential in the clinic, and which are closest to reaching the market?
- How effective are current therapies for these indications, and how have they been able to improve the general prognosis in recent decades?
- Which molecule types and molecular targets are most prominent across transplantation therapy?
- Which specific types of transplantation are being most heavily studied across the pharmaceutical pipeline?


Browse TOC @ https://www.researchmoz.us/frontier-pharma-transplantation-therapeutics-a-highly-innovative-pipeline-with-a-range-of-adaptive-and-innate-immune-targeting-programs-focusing-on-graft-versus-host-disease-and-kidney-transplantation-report.html/toc


Reasons to buy
- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options for transplantation rejection.
- Identify leading products and key unmet needs within the market.
- Recognize trends in pipeline innovation by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix assessment, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

Future Prospects Of Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

Researchmoz added Most up-to-date research on "Future Prospects Of Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" to its huge collection of research reports.

This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.
Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. This pipeline is far smaller; there are a total of nine products in development for this indication, by six companies and two academic institutions.


Scope
  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?


Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Rising Demand For Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

Researchmoz added Most up-to-date research on "Rising Demand For Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017" to its huge collection of research reports.

This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman's external genitals, called the vulva.
The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.


Scope
  • Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?


Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Air Powered Vehicle In Global Market Will Grow At A CAGR Of 70.80% Over The Forecast Period 2018 - 2026

Researchmoz added Most up-to-date research on "Air Powered Vehicle In Global Market Will Grow At A CAGR Of 70.80% Over The Forecast Period 2018 - 2026" to its huge collection of research reports.

This report analyzes and forecasts the market for air powered vehicle at the global and regional level. The market has been forecasted based on revenue (US$ Mn) and volume (thousand units) from 2018 to 2026. The study includes drivers and restraints of the global air powered vehicle market. It also covers the impact of these drivers and restraints on the demand for air powered vehicle during the forecast period. The report also highlights opportunities and future scope in the air powered vehicle market at the global and regional level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global air powered vehicle market. The Porter’s Five Forces model for the air powered vehicle market has also been included to help understand the competitive landscape in the market. The study encompasses market attractiveness analysis, wherein technology is benchmarked based on market size, growth rate, and general market share.
The study provides a decisive view of the global air powered vehicle market by segmenting it in terms of energy mode, vehicle type, and geography. These segments have been analyzed based on present and future trends. Regional segmentation includes the current and forecast demand for air powered vehicle in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers the demand for individual segments in all major countries across all regions.


The study includes profiles of major companies operating in the global air powered vehicle market. Market players have been profiled in terms of attributes such as company overview, financial overview, business strategies, recent developments, key executive bios, and manufacturing footprint.
The report provides the estimated market size of air powered vehicle for 2017 and forecast for the next nine years. The global market size of air powered vehicle has been provided in terms of revenue and volume. Market numbers have been estimated based on energy mode, vehicle type, and geography segments of air powered vehicle. Market size and forecast for each energy mode and vehicle type have been provided in terms of global and regional/country markets.
In order to compile the research report, we conducted in-depth interviews and discussions with a number of key industry participants and opinion leaders. Primary research represents the bulk of research efforts, supplemented by extensive secondary research. We reviewed key players’ product literature, annual reports, press releases, and relevant documents for competitive analysis and market understanding. Secondary research also includes a search of recent trade, technical writing, internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise market data, capturing industry participants’ insights, and recognizing business opportunities.


Secondary research sources that are typically referred to include, but are not limited to company websites, annual reports, financial reports, broker reports, investor presentations, and SEC filings, internal and external proprietary databases, and relevant patent and regulatory databases, national government documents, statistical databases, and market reports, news articles, press releases, and webcasts specific to companies operating in the market, National government documents, statistical databases, and market reports, American Automobile Association, European Automobile Manufacturers Association, Automotive Research Association of India, Organisation Internationale des Constructeurs d'Automobile (OICA), UITP, Factiva, etc.
Primary research involves e-mail interactions, telephonic interviews, linked interviews, and face-to-face interviews for each market, category, segment, and sub-segment across geographies. We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate the data and analysis. Primary interviews provide firsthand information on market size, market trends, growth trends, competitive landscape, and outlook, etc. These help validate and strengthen secondary research findings. These also help develop the analysis team’s expertise and market understanding.
The global air powered vehicle market has been segmented as follows:
Global Air Powered Vehicle Market, by Energy Mode
  • Single Energy Mode
  • Dual Energy Mode
Global Air Powered Vehicle Market, by Vehicle Type
  • Passenger Vehicles
  • Commercial Vehicles
Global Air Powered Vehicle Market: by Region/Country/Sub-region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

Barium Carbonate Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Researchmoz added Most up-to-date research on "Barium Carbonate Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026" to its huge collection of research reports.

Barium carbonate is a water-insoluble salt which is primarily used for the removal of efflorescence from bricks and tiles. Barium carbonate is found in three different forms: powder, granular, and ultra-fine. Powder form of barium carbonate is highly used. Barium carbonate is widely used in applications such as bricks, tiles, and specialty glass. It is also used as an ingredient in glazes, frits, and enamels. Barium carbonate acts as a flux, matting agent, and crystallizing agent. It is employed in the production of specialty glass, as it gives a bright final finish. Application of barium carbonate in the production of electro-ceramic materials is anticipated to offer attractive growth opportunities to the barium carbonate market in the next few years.
Addition of barium carbonate, even in small amounts, to the mixture prior to fire hardening and calcination prevents scumming in bricks and tiles. Barium carbonate reacts with soluble sulfates to form insoluble carbonates and sulfates that do not produce scum. Bricks is a highly important building material for use in construction activities in developing economies. The construction industry in both China and India has been expanding over the last few years. This is fueling the demand for bricks and flooring tiles in these countries. This, in turn, is propelling the barium carbonate market in China and India. Demand for barium carbonate from the electro-ceramics industry is on the rise. Barium carbonate is utilized in multilayered ceramic capacitors, PTC thermistors, piezoelectric transducers, sensors, dynamic RAM, MEMS, optical modulators, and electromechanical devices.


Based on form, the global barium carbonate market has been classified into granular, powder, and ultra-fine. The powder segment dominates the global barium carbonate market, owing to use of powder form of the compound in matt glazes, specialty glass, clay bricks, and tiles. Ultra-fine barium carbonate is used in brine purification. Key properties of granular form of barium carbonate include high bulk density and compatibility with other raw materials. In terms of application, the global barium carbonate market has been segmented into specialty glass, bricks & tiles, chemical compounds, glazes, frits, and enamels, electro-ceramic materials, and others.
Based on region, the global barium carbonate market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominates the global market. Several favorable government policies and public–private partnership programs have boosted infrastructure development and construction activities in countries such as China, Indonesia, the Philippines, Thailand, and India. Furthermore, rise in the purchasing power of consumers is propelling the building & construction industry in Asia Pacific.
The report analyzes and forecasts the market for barium carbonate at the global and regional levels. The market has been projected in terms of volume (tons) and revenue (US$ Thousand) from 2018 to 2026. The study includes drivers and restraints of the global barium carbonate market. It also covers the anticipated impact of these drivers and restraints on the demand for barium carbonate during the forecast period. The report also highlights opportunities for growth of the barium carbonate market at the global and regional levels.


The report comprises detailed value chain analysis, which provides a comprehensive view of the global barium carbonate market. Porter’s five forces model for the market has also been included to help understand the competition landscape of the market. The study encompasses market attractiveness analysis, wherein application segments have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the global barium carbonate market by segmenting it in terms of form, application, and region. These application and regional segments have been analyzed based on the present and future trends. Regional segmentation includes the current and forecast demand for barium carbonate in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers individual application segments of the market in all regions.
The study includes profiles of major companies operating in the global barium carbonate market. Key players profiled in the report include Guizhou Red Star Development Co., Ltd, Sakai Chemical Industry Co., Ltd, Hebei Xinji Chemical Group Co., Ltd, Hebei Xinji Chemical Group Co., Ltd , Shaanxi Ankang Jiangshua Group Co., Ltd, and Vishnu Chemicals. These players account for a major share of the global market. Also, they are forward integrated. Brand promotions and launch of new products are likely to raise sales of barium carbonate in the next few years. Market leaders look for different measures such as strategic pricing and form improvement to increase their profit margin.
The report provides the estimated market size of the global barium carbonate market for 2017 and forecast for the next nine years. The size of the global market has been provided in terms of revenue. Market numbers have been estimated based on form, application, and regional segments. Market size and forecast for each form and application segment have been provided for global as well as regional markets.
Global Barium Carbonate Market, by Form
  • Granular
  • Powder
  • Ultra-fine
Global Barium Carbonate Market, by Application
  • Specialty Glass
  • Bricks & Tiles
  • Chemical Compounds
  • Glazes, Frits, and Enamels
  • Electro-ceramic Materials
  • Others
Global Barium Carbonate Market, by Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Russia & CIS
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Egypt
    • Rest of Middle East & Africa
Key Takeaways
  • The report provides extensive analysis of market trends from 2017 to 2026 in order to identify growth opportunities and market developments
  • It provides comparative analysis of various application industries wherein barium carbonate is used
  • The report provides detailed information on the manufacturing process of barium carbonate
  • It gives detailed information on the import/export scenario of the barium carbonate market
  • It identifies key factors to build a roadmap for upcoming growth opportunities for the barium carbonate market at the global, regional, and country levels
  • The report offers comprehensive analysis with respect to investments and regulatory scenario that would subsequently impact the outlook and forecast for the global barium carbonate market between 2018 and 2026
  • The report provides a detailed competition landscape of key players operating in the market in order to understand the competition level
  • It covers the global supply–demand scenario of the barium carbonate market and the global production of barium carbonate
  • It provides a list of customers of barium carbonate along with their contact details
  • The report provides detailed pricing analysis based on form and key players
  • The report offers Porter’s five forces analysis to highlight the power of buyers and suppliers